Eisai Co., Ltd. (TYO: 4523) and Biogen Inc. (NASDAQ: BIIB) announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Supplemental Biologics License Application (sBLA) for LEQEMBI (lecanemab‑irmb) subcutaneous autoinjector (SC‑AI) – branded LEQEMBI IQLIK – as a once‑weekly starting dose for early Alzheimer’s disease, with a PDUFA action date of May 24, 2026.
Contents
Regulatory Milestone
| Item | Detail |
|---|---|
| Companies | Eisai Co., Ltd. (TYO: 4523) and Biogen Inc. (NASDAQ: BIIB) |
| Drug | LEQEMBI IQLIK (lecanemab‑irmb subcutaneous autoinjector) |
| Application | sBLA (Supplemental Biologics License Application) |
| Agency | U.S. FDA |
| Review Status | Priority Review |
| PDUFA Date | May 24, 2026 |
| Current IV Status | Approved (bi‑weekly IV infusion) |
| Proposed Regimen | Once‑weekly 500 mg SC (two 250 mg injections) |
Drug Profile & Administration Advantage
- Mechanism: Anti‑amyloid beta (Aβ) protofibril antibody that clears toxic amyloid plaques in early Alzheimer’s disease
- Current Standard: Bi‑weekly IV infusion (1‑hour clinic visit)
- LEQEMBI IQLIK Innovation: Subcutaneous autoinjector enabling home administration by patients or caregivers
- Clinical Benefit: Weekly SC dosing achieves equivalent drug exposure to bi‑weekly IV with similar clinical and biomarker efficacy
- Safety Profile: <2 % incidence of systemic injection/infusion‑related reactions (comparable to IV)
Clinical Evidence – Clarity AD OLE Sub‑Studies
| Endpoint | SC‑AI 500 mg Weekly | IV 10 mg/kg Bi‑Weekly | Comparison |
|---|---|---|---|
| Pharmacokinetic Exposure | Equivalent | Standard | Non‑inferior |
| Amyloid Clearance | Similar | Standard | Comparable |
| Clinical Efficacy (CDR‑SB) | Maintained | Standard | Comparable |
| Infusion/Injection Reactions | <2 % | 12‑15 % | Favorable |
| Patient Convenience | Home administration | Clinic required | Significant advantage |
- Patient Impact: Eliminates bi‑weekly clinic visits (26 visits/year → 52 home injections/year), reducing caregiver burden and improving adherence
- Caregiver Benefit: Autoinjector design simplifies administration vs. IV infusion setup
Market Impact & Commercial Outlook
| Parameter | 2026E | 2027E | 2028E |
|---|---|---|---|
| Global Early AD Patients | 8.5 million | 8.8 million | 9.1 million |
| LEQEMBI IV Market Share | 18 % | 22 % | 25 % |
| SC‑AI Uptake (if approved) | 0 % | 35 % of new patients | 55 % of total |
| Annual US Price (SC‑AI) | – | $26,500 | $26,500 |
| Eisai/Biogen Revenue (LEQEMBI) | $1.1 billion | $1.8 billion | $2.4 billion |
- Competitive Landscape:
- Donanemab (Eli Lilly) – IV infusion only; no SC formulation in development
- Kisunla (Eli Lilly) – Similar IV requirement
- LEQEMBI IQLIK – First and only SC anti‑amyloid therapy with home administration option
- Market Expansion: SC formulation expected to accelerate patient enrollment by 30‑40 % due to convenience advantage
- Reimbursement: CMS coverage already established for IV; SC expected to qualify for same billing codes with additional home health benefit
Strategic Positioning
- Manufacturing: Eisai’s Indianapolis facility will produce SC formulation; autoinjector device supplied by Ypsomed
- Launch Readiness: Q3 2026 US launch anticipated upon approval; EU filing planned for Q4 2026
- Patient Support: LEQEMBI CarePath program will provide home nursing training for SC administration
- Patent Extension: New formulation extends market exclusivity to 2032 (vs. 2030 for IV)
Forward‑Looking Statements
This brief contains forward‑looking statements regarding FDA approval timelines, commercial adoption rates, and revenue forecasts for LEQEMBI IQLIK. Actual results may differ due to regulatory review outcomes, competitive dynamics, and reimbursement policies.-Fineline Info & Tech
